SCHEMBL9909228

SCHEMBL9909228

COc1ccc(-c2ccnc3c(C)cc(C(=O)O)cc23)c(Cl)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.43
KDM4C Q9H3R0 1/20 0.43
KDM5B Q9UGL1 1/20 0.43
LMNA P02545 1/20 0.41
MRGPRX4 Q96LA9 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
CDC7 O00311 2/20 0.39
DBF4 Q9UBU7 2/20 0.39
CCNT1 O60563 1/20 0.39
CSNK2A2 P19784 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
CSNK1A1 P48729 1/20 0.39
CSNK1D P48730 1/20 0.39
CDK9 P50750 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39
EIF4E P06730 1/20 0.39
PRKAB2 O43741 4/20 0.38
PRKAG1 P54619 4/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9909259 0.90 CDC7 (0.38) KDM5AKDM4CKDM5BLMNAPTGDR2
SCHEMBL15500536 0.88 CDC7 (0.39) KDM5AKDM4CKDM5BLMNAPTGDR2
SCHEMBL9907459 0.86 KDM4C (0.45) KDM4CKDM5BMRGPRX4KDM4ESMN1; SMN2
SCHEMBL9907495 0.86 PTGDR2 (0.41) KDM5AKDM4CKDM5BMRGPRX4PTGDR2
SCHEMBL9909233 0.85 CDC7 (0.39) KDM5AKDM4CKDM5BCDC7DBF4
SCHEMBL9907428 0.84 MAPK14 (0.43) KDM5AKDM4CKDM5BCYP1A2
SCHEMBL9909167 0.82 CCNT1 (0.42) KDM5AKDM4CKDM5BMRGPRX4PTGDR2
SCHEMBL12874648 0.81 CDC7 (0.37) KDM5AKDM4CKDM5BPTGDR2CDC7
SCHEMBL9907512 0.80 KDM4C (0.47) KDM5AKDM4CKDM5BMRGPRX4PTGDR2
SCHEMBL9909218 0.78 PRKAB2 (0.39) KDM5AKDM4CKDM5BLMNAMRGPRX4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8853242-B2 Nitrogenous-ring acylguanidine derivative ASTELLAS PHARMA INC. (JP) 2014-10-07 US disclosed
EP-2463276-B1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC (JP) 2014-03-12 EP disclosed
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2012-06-07 US disclosed
WO-2011016504-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE アステラス製薬株式会社 (JP) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142727-A1 NITROGENOUS-RING ACYLGUANIDINE DERIVATIVE HTR5A, HTR2A, HTR1E KDM5A 172/4885KDM4C 1366/4885KDM5B 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.